Avid Bioservices Partners With California Institute For Regenerative Medicine To Provide CDMO Services For Cell And Gene Therapy Programs
Portfolio Pulse from Benzinga Newsdesk
Avid Bioservices, Inc. (NASDAQ:CDMO) has announced a partnership with the California Institute for Regenerative Medicine (CIRM) to provide development and CGMP manufacturing services to CIRM-funded programs. The collaboration aims to support the manufacturing of adeno-associated adenovirus (AAV), as well as other cell and gene therapy (CGT) programs within California. Avid will assist CIRM's partners in accelerating gene therapy development and manufacturing through its suite of CDMO services.
November 08, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avid Bioservices' partnership with CIRM could potentially boost its revenues and reputation in the biotech industry, as it will provide development and manufacturing services for cell and gene therapy programs.
The partnership with CIRM will allow Avid Bioservices to provide its development and manufacturing services to CIRM-funded programs, potentially leading to increased revenues and a stronger reputation in the biotech industry.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100